Dihydrotestosterone (DHT)

Catalog No.S4757 Synonyms: androstanolone, stanolone, 5α-DHT

For research use only.

Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.

Dihydrotestosterone (DHT) Chemical Structure

CAS No. 521-18-6

Selleck's Dihydrotestosterone (DHT) has been cited by 14 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Other Androgen Receptor Products

Biological Activity

Description Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.
Targets
Androgen Receptor [1]
()
In vitro

In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels. DHT additionally upregulated the levels of phosphorylation of EGFR (pEGFR) and its downstream proteins AKT (pAKT) and ERK1/2 (pERK), induced by EGF treatment, in AR-positive cells[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CV-1 cell NITYd4tHfW6ldHnvckBie3OjeR?= NU\k[m5CSWexbnnzeIlkKGGldHn2bZR6KCiHQ{WwLUBi\2GrboP0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXi1zIHPlcIwtKEWFNUC9NE4xODZizszN NUTUNllwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUi3NVU{PCd-OUi3NVU{PDxxYU6=
MDA-MB-453 cell NGTKOGVHfW6ldHnvckBie3OjeR?= MX\EbZNxdGGlZX3lcpQhd2ZiW{PIYWRJXCCocn;tJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBOTEFvTVKtOFU{KGOnbHzzJIJ6KHeqb3zlJINmdGxicnXj[ZB1d3JiYnnu[Ilv\yCjc4PhfUwhU2l;MD6wNFAzKM7:TR?= NInNRWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{CzOFEyPyd-MUewN|QyOTd:L3G+
HepG2 cell Mo\DSpVv[3Srb36gZZN{[Xl? MU\BZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[WO2aY\heIlwdixiSVO1NF0xNjBzOEKg{txO MnnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzNEm4OlYoRjF5MUS5PFY3RC:jPh?=
MDA453 cell NGDVVHFHfW6ldHnvckBie3OjeR?= MkP1SIl{eGyjY3Xt[Y51KG:oIGuzTH1FUFRiZoLvcUBpfW2jbjDBVkBqdiCPRFG0OVMh[2WubIOsJGtqRTBwMECzJO69VQ>? NFrqOnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G4NVE1OSd-MUexPFEyPDF:L3G+
mouse C2C12 cell MYLGeY5kfGmxbjDhd5NigQ>? NWfQXmVRSWexbnnzeEBi[3Srdnn0fUBifCC{YYSgRXIhfHKjboPm[YN1\WRiaX6gcY92e2ViQ{LDNVIh[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTB;MD6wNlgh|ryP Mn\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzOEGxOFEoRjF5MUixNVQyRC:jPh?=
monkey COS7 cell M1u3TmZ2dmO2aX;uJIF{e2G7 MmDrRolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hdW:wa3X5JGNQWzdiY3XscJMh[nlid3jvcIUh[2WubDDibY5lcW6pIHHzd4F6NCCNaU2wMlAxODJizszN MmHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NEK5NVIoRjF6NESyPVEzRC:jPh?=
CHO cell MlHjSpVv[3Srb36gZZN{[Xl? M1v6dGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGdTPSCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIJ6KGy3Y3nm[ZJie2ViYYPzZZktKEWFNUC9OE41QSEQvF2= Mnf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|MEeyPVQoRjF6M{C3Nlk1RC:jPh?=
COS7 cell NFjLcWxHfW6ldHnvckBie3OjeR?= NGnEUZpC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJHc4PDGFIH31eIFvfCCneIDy[ZN{\WRiaX6gR29UPyClZXzsd{Bie3Onc4Pl[EBieyCudXPp[oVz[XOnIHHjeIl3cXS7IHHmeIVzKDJ2IHjyd{BjgSC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMEGyJO69VQ>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB7NEK3PUc,OjJyOUSyO|k9N2F-
COS7 cell M{D3O2Z2dmO2aX;uJIF{e2G7 MWLB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IGS4O|dCKG23dHHueEBmgHC{ZYPz[YQhcW5iQ1;TO{Bk\WyuczDhd5Nme3OnZDDhd{BtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFI1KGi{czDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODF3IN88US=> M4TvWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEm0Nlc6Lz5{MkC5OFI4QTxxYU6=
COS7 cell M4rpZmZ2dmO2aX;uJIF{e2G7 NYnjeVJGSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iQ1;TO{Bk\WyuczDhd5Nme3OnZDDhd{BtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFI1KGi{czDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODB4MjFOwG0> NGXmRmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5OFI4QSd-MkKwPVQzPzl:L3G+
LNCaP-hr cell Ml[wSpVv[3Srb36gZZN{[Xl? NXf0UYVnOyCmYYnz MkC5RYdwdmm|dDDhZ5Rqfmm2eTDheEBCdmS{b3flckBz\WOncITvdkBVQDd5QTDteZRidnRiaX6gbJVu[W5iTF7DZXAucHJiY3XscJMh[XO|ZYPz[YQh[XNicILvd5RifGVic4DlZ4lncWNiYX70bYdmdiC|ZXPy[ZRqd25ibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KGWweont[U1qdW23bn;hd5NigSxiRVO1NF0xNjBzNTFOwG0> MkiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzOUm0O|coRjJ|MUm5OFc4RC:jPh?=
LNCaP-hr cell NFf2ZXFHfW6ldHnvckBie3OjeR?= NEDS[lU{KGSjeYO= NUfWfoFDSWexbnnzeEBi[3Srdnn0fUBifCC5aXzkJJR6eGViQX7kdo9o\W5icnXj[ZB1d3JiaX6gbJVu[W5iTF7DZXAucHJiY3XscJMh[XO|ZYPz[YQh[XNicILvd5RifGVic4DlZ4lncWNiYX70bYdmdiC|ZXPy[ZRqd25ibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KGWweont[U1qdW23bn;hd5NigSxiRVO1NF0xNjByNkKg{txO MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzOUm0O|coRjJ|MUm5OFc4RC:jPh?=
HEK293 cell NVnhbm9{TnWwY4Tpc44h[XO|YYm= NVWzVoluSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkG4JI5O MmrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|MEW2PFgoRjJ3M{C1Olg5RC:jPh?=
COS M375bWZ2dmO2aX;uJIF{e2G7 NUfh[HdPSmmwZHnu[{Bi\m[rbnn0fUBi\2GrboP0JGFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBEV1NiY3XscJMtKEurIE2gNE4xODJizszNMi=> M4jQO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl6N{G1N|QoRjl6N{G1N|Q9N2F-
COS-1 MljVSpVv[3Srb36gZZN{[Xl? NVfPNFlvSmmwZHnu[{Bi\m[rbnn0fUBnd3JiaIXtZY4hSW6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV{0yKGOnbHzzMEBMcSB;IECuNFA{KM7:TT6= NIrFVGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OUK1O|I2Lz57OUK1O|I2RC:jPh?=
CV-1 M1TLOmZ2dmO2aX;uJIF{e2G7 MkSzRYdwdmm|dDDhZ5Rqfmm2eTDh[4FqdnO2IFj1cYFvKEGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDDWk0yKGOnbHzzMEBGSzVyIE2gNE4xODVizszNMi=> NYnMUos2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUmyOVczPSd-OUmyOVczPTxxYU6=
COS NFnle|hHfW6ldHnvckBie3OjeR?= Mlm0TY4hfmm2cn:gZolv\GmwZzDh[oZqdmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjD0doFve2[nY4Tl[EBqdnSxIFPPV{Bk\Wyucz6sJGlEPTBiPTCwMlAxPCEQvF2u M4HSelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyMkOwOlI5Lz5zMEKzNFYzQDxxYU6=
CV-1 NUCwcI0zTnWwY4Tpc44h[XO|YYm= MYjJckB3cXS{bzDh[49vcXO2aXOgZYN1cX[rdImgZYdicW6|dDDoeY1idiCjbnTyc4dmdiC{ZXPldJRweiC3c3nu[{Bkd3S{YX7z[oVkfGmxbjDhd5NigSCrbjDDWk0yKGOnbHzzMkwhTUN3MDC9JFAvODB4IN88UU4> M3fCblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyMkOwOlI5Lz5zMEKzNFYzQDxxYU6=
CV-1 M3jIWmZ2dmO2aX;uJIF{e2G7 Mnf2RYdwdmm|dDDhZ5Rqfmm2eTD0c{B1cGViaIXtZY4h[W6mcn;n[Y4hemWlZYD0c5IhMGiDUjmgbY4hS1ZvMTDj[YxteyxiRVO1NEA:KDBwMEC2JO69VS5? NFzaV2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEO0NFYzPCd-MUCzOFA3OjR:L3G+
CV1 M1;j[2Z2dmO2aX;uJIF{e2G7 MV;B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHnuJGNXOSClZXzsd{Bu\WG|dYLl[EBieyC|dHnteYxifGmxbjDv[kBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdImgZpkh[2:2cnHud4Zm[3Srb36gZZN{[XluIFXDOVAhRSByLkCwOVEh|ryPLh?= M1HhTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MEO0NVE4Lz5zN{CzOFEyPzxxYU6=
CV1 NHX2W4lHfW6ldHnvckBie3OjeR?= NUL4RVZvSmmwZHnu[{Bi\m[rbnn0fUB1dyCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iQ2[xJINmdGy|LDDLbUA:KDBwMECwNkDPxE1w NXfKfJhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVc5OzhpPkG3NlU4QDN6PD;hQi=>
CV1 NUTUOpo3TnWwY4Tpc44h[XO|YYm= MWfB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMtKEWFNUCgQUAxNjByNUGg{txONg>? NX3Ue213RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUeyOVc5OzhpPkG3NlU4QDN6PD;hQi=>
MDA-MB-453 MojDSpVv[3Srb36gZZN{[Xl? MkXKSIl{eGyjY3Xt[Y51KG:oIGuzTH1FUFRiZoLvcUBpfW2jbjDBVkBmgHC{ZYPz[YQhcW5iTVTBMW1DNTR3MzDj[YxteyxiS3mgQUAxNjByMEOg{txONg>? M4n2e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEO5NVEzLz5zN{SzPVEyOjxxYU6=
CV1 MVHGeY5kfGmxbjDhd5NigQ>? MkjvRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS1ZzIHPlcIx{KGK7IITyZY5{[3KrcITpc45idCCjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwJF0hOC5yMEW3JO69VS5? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzR|OUGxNkc,OTd2M{mxNVI9N2F-
CV1 NXnvVWh{TnWwY4Tpc44h[XO|YYm= NXfUVXlJSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iQ2[xJINmdGy|IHL5JJRz[W6|Y4LpdJRqd26jbDDhZ5RqfmG2aX;uJIF{e2G7LDDFR|UxKD1iMD6wNFU4KM7:TT6= M1TXcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5N{CzPVM5Lz5zN{ewN|k{QDxxYU6=
MDA-MB-453 NX2yfpZITnWwY4Tpc44h[XO|YYm= NEDVVXFFcXOybHHj[Y1mdnRib3[gX|NJZUSKVDDmdo9uKGi3bXHuJGFv\HKxZ3XuJJJm[2WydH;yJIlvKGi3bXHuJG1FSS2PQj20OVMh[2WubIOsJGtqKD1iMD6wNFA6KM7:TT6= NV\1TGhwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NFA1QTlpPkG4OFAxPDl7PD;hQi=>
CV1 MVHGeY5kfGmxbjDhd5NigQ>? MWTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHnuJGNXOSClZXzsd{BjgSC2cnHud4NzcXC2aX;uZYwh[WO2aY\heIlwdiCjc4PhfUwhTUN3MDC9JFAvODB3NzFOwG0v MnvQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MEC0PVkoRjF6NECwOFk6RC:jPh?=
Saos2 MULGeY5kfGmxbjDhd5NigQ>? NFTuSG1C[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCrbjDoeY1idiCVYX;zNkBk\WyuczDhd5Nme3OnZDDhd{BKVDZicnXwdoV{e2mxbjygTWM2OCB;IECuNFAxODVizszNMi=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR2MkmxNkc,OTh2NEK5NVI9N2F-
CV1 NHfQXlNHfW6ldHnvckBie3OjeR?= NUjsSIZYSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBi\nKrY3HuJIdz\WWwIH3vcotmgSCFVkGgZ4VtdHNiYomgZ491emGwc3\lZ5Rqd25iYYPzZZktKEWFNUCgQUAxNjByNUGg{txONg>? NFvyXpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES0NlkyOid-MUi0OFI6OTJ:L3G+
MDA-kb2 M1juWmZ2dmO2aX;uJIF{e2G7 MlzERYdwdmm|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBqdiCqdX3hckBOTEFva3KyJINmdGy|IHHzd4V{e2WmIHHzJJN1cW23bHH0bY9vKG:oIHz1Z4ln\XKjc3WgZYN1cX[rdImgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|E2OCB;IECuNFAxPSEQvF2u MmLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3OUKyOFUoRjF7NUmyNlQ2RC:jPh?=
MDA-kb2 M3PTPGZ2dmO2aX;uJIF{e2G7 MXvB[49vcXO2IHHjeIl3cXS7IHH0JIdtfWOxY3;yeIlkd2mmIILlZ4VxfG:{IHnuJIh2dWGwIF3ERU1s[jJiY3XscJMh[XO|ZYPz[YQh[XNic4TpcZVt[XSrb36gc4YhdHWlaX\ldoF{\SCjY4Tpeol1gSCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFMUWwJF0hOC5yMEC1JO69VS5? Ml:xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3OUKyOFUoRjF7NUmyNlQ2RC:jPh?=
MDA-MB-453 NV23XpdFTnWwY4Tpc44h[XO|YYm= M3;NeWRqe3CuYXPlcYVvfCCxZjDbN2hedWW2aInseJJq\W6xbH;u[UBnem:vIHHu[JJw\2WwIILlZ4VxfG:{IHnuJIh2dWGwIF3ERU1OSi12NUOgZ4VtdHNuIFnDOVAhRSByLkCwNUDPxE1w M{fWT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkC2PFcxLz5zOU[wOlg4ODxxYU6=
MDA-MB-453 NW[1UoIzTnWwY4Tpc44h[XO|YYm= M{jh[mFod26rc4SgZYN1cX[rdImgZZQh[W6mcn;n[Y4hemWlZYD0c5IhcW5iaIXtZY4hVUSDLV3CMVQ2OyClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJG1OXFZvTGXDJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDNUXRXNUyWUj;wdo9ud3SncjDsbY5s\WRiTGXDJIdmdmViYomgcJVkcW[ncnHz[UB1emGwc3HjeIl3[XSrb36gZZN{[XluIFXDOVAhRSByLkCwNkDPxE1w MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZyNki3NEc,OTl4ME[4O|A9N2F-
NIH3T3 M4\xN2Z2dmO2aX;uJIF{e2G7 Mn3CRYdwdmm|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBNSkRiVEi3O2EhdXW2YX70JIlvKG2xdYPlJG5KUDOWMzDj[YxteyC2cnHud4lmdnSueTD0doFve2[nY4Tl[EB4cXSqIHLleIEu\2GuYXP0c5Nq\GG|ZTDy[ZBwenSncjDn[Y5mKGG|c3Xzd4VlKGG|IHPlcIx2dGG{IITyZY5{\m:{bXH0bY9vKGK7IGKtV2FVKGG|c3H5MEBGSzVyIE2gNE4xODF{NUmg{txONg>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh3NkmyNUc,OTl6NU[5NlE9N2F-
NIH3T3 MnL3SpVv[3Srb36gZZN{[Xl? MoLORYdwdmm|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBqdiCvb4Xz[UBPUUh|VEOgZ4VtdHNidILhcpNq\W62bImgeJJidnOoZXP0[YQhf2m2aDDi[ZRiNWejbHHjeI9{cWSjc3WgdoVxd3K2ZYKg[4Vv\SCjc4Pld5Nm\CCjczDj[YxtfWyjcjD0doFve2[xcn3heIlwdiCkeTDSMXNCXCCjc4PhfUwhTUN3MDC9JFAvODB|OUixJO69VS5? MlXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6NU[5NlEoRjF7OEW2PVIyRC:jPh?=
COS7 NVvsPFQ5TnWwY4Tpc44h[XO|YYm= MVfB[49vcXO2IHHjeIl3cXS7IHH0JIFv\HKxZ3XuJJJm[2WydH;yJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCneIDy[ZN{\WRiaX6gZYZzcWOjbjDndoVmdiCvb37r[ZkhS0:VNzDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQuTEKGIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMEKg{txONg>? NW\YU5dKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4OlMxQDNpPkG5PFY{ODh|PD;hQi=>
Freestyle293F M1vOUmZ2dmO2aX;uJIF{e2G7 M1LDUFMhcHK| MVHEbZNxdGGlZX3lcpQhd2ZiW{G3MYFteGijLX3leIh6dC1|SG2tcYljd2yncn;u[UBnem:vIHj1cYFvKGGwZILv[4VvKHKnY3XweI9zKGW6cILld5Nm\CCrbjDISWszQTNiZHXybZZm\CCIcnXlV5R6dGV{OUPGJINmdGy|IHHmeIVzKDNiaILzMEBKSzVyIE2gNE4xODJzIN88UU4> MlnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOUSyO|koRjJ{MEm0Nlc6RC:jPh?=
Freestyle293F MnvhSpVv[3Srb36gZZN{[Xl? NEPyXYY{KGi{cx?= NUDkfZZtTGm|cHzhZ4Vu\W62IH;mJHsyPy2jbIDoZU1u\XSqeXytN2heNW2rYn;s[ZJwdmViZoLvcUBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDUPFc4SSCvdYThcpQh\XiycnXzd4VlKGmwIFjFT|I6OyCmZYLpeoVlKE[{ZXXTeJlt\TJ7M1[gZ4VtdHNiYX\0[ZIhOyCqcoOsJGlEPTBiPTCwMlAxOjZizszNMi=> NH21[|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5OFI4QSd-MkKwPVQzPzl:L3G+
HeLa NEXLU4NHfW6ldHnvckBie3OjeR?= MnnzWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IITyZY5{\mWldHXkJIlvKGi3bXHuJGhmVGFiY3XscJMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBC[3Srdnn0fUA:KDBwMEC4JO69VS5? NYTyWnU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4PVc3OTFpPkKyPFk4PjFzPD;hQi=>
HeLa NV72cFJqTnWwY4Tpc44h[XO|YYm= NVjIZ2Q3WGG{dHnhcEBi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCKZVzhJINmdGy|IHPvMYV5eHKnc4PpcochSVKHIHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDiZZNm\CC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGFkfGm4aYT5JF0hOC5yMEig{txONg>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl3N{m0O{c,OjJ7NUe5OFc9N2F-
Freestyle293F M4XPfWZ2dmO2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCDbnTyc4dmdiC{ZXPldJRweiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDGdoVme3S7bHWyPVNHKGOnbHzzMEBKSzVyIE2gNE4xODJzIN88UU4> NGf4d|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G5PVQ4Pyd-MkOxPVk1Pzd:L3G+
Freestyle293F NFm3UppHfW6ldHnvckBie3OjeR?= NGnKTGFKdmirYnn0bY9vKG:oIFHu[JJw\2WwIILlZ4VxfG:{IGS4O|dCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCIcnXld5R6dGV{OUPGJINmdGy|LDDJR|UxKD1iMD6wNFI3KM7:TT6= M3nsWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUm5OFc4Lz5{M{G5PVQ4PzxxYU6=
COS7 MnnwSpVv[3Srb36gZZN{[Xl? NUDGbYk6OiCqcoO= NIHGOHRFcXOybHHj[Y1mdnRib3[gX|NJZSCfNXHsdIhiNUSKVDDmdo9uKG2xdYPlJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCvb37r[ZkhS0:VNzDj[YxteyCjZoTldkAzKGi{czDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pIHHuZYx6e2m|LDDJR|UxKD1iMD6wNFEh|ryPLh?= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV{N{ixOkc,OjN3Mke4NVY9N2F-
C2C12 NVzTUlB3TnWwY4Tpc44h[XO|YYm= MnGxOUBl[Xm| MkSzRYdwdmm|dDDhZ5Rqfmm2eTDheEBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5ibX;1d4UhSzKFMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgc5N1\W:kbHHzeEBlcW[oZYLlcpRq[XSrb36gZYZ1\XJiNTDkZZl{NCCHQ{WwJF0hOC5yMECwOUDPxE1w M{HJUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlkxLz5{NEmwNFI6ODxxYU6=
C2C12 M1n4ZWZ2dmO2aX;uJIF{e2G7 NIfDZWlC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCvb4Xz[UBEOkNzMjDj[YxteyCkeTDhcoRzd2enbj3zdIVkcW[rYzDy[ZNxd26|ZTDlcIVu\W62LXTybZZmdiCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTBiPTCwMlAxODF|IN88UU4> M{TVNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKxPVY1Lz5{NUGyNVk3PDxxYU6=
COS7 MX7GeY5kfGmxbjDhd5NigQ>? MlywNlQhcHK| M{jyV2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gRXIh\XiycnXzd4VlKGmwIFHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNQWzdiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMECzJO69VS5? MoP4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NUS4OFkoRjJ6NEW0PFQ6RC:jPh?=
Shionogi NYO0cGptTnWwY4Tpc44h[XO|YYm= NGmzUWwyOCCyTR?= NGDPXlJKdmS3Y4Tpc44hd2ZicILvcIln\XKjdHnvckBw\iCvb4Xz[UBUcGmxbn;nbUBk\WyuczDheEAyOCCyTR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzdzMUi1OUc,OTd5MUG4OVU9N2F-
MCF7 NXzDW3RETnWwY4Tpc44h[XO|YYm= Mn;QN|AhfU1? NYfXPXU6OjRiaILz NX\hPIptSW62YXfvcol{fCCjY4Tpeol1gSCjdDDBVkBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBCWiCuZY\lcEBifCB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{KHKnbHH0bZZmKHSxIHPvcpRzd2x? NX7lZotnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNVQ4PTFpPkKyNFE1PzVzPD;hQi=>
Assay
Methods Test Index PMID
Western blot Cyclin D1 / Cyclin D2 / Cyclin D3 / Cyclin E2 / Cyclin A1 / AR ; p-CDK2 / CDK2 / CDK4 / CDK6 / CDKN1A / p-RB / RB ; p27 / p-p27 ; AR / PP1 26372468 22139837 26636645
Immunofluorescence FOXO1 / p27 ; AKT(S473) / PKCα(S657) 22139837
In vivo DHT-treated SOD1-G93A mice demonstrate ameliorated muscle atrophy and increased body weight, which is associated with stronger grip-strength. DHT treatment increases the expression of insulin-like growth factor-1 in muscle, which can exert myotrophic as well as neurotrophic effects through retrograde transport. DHT treatment attenuates neuromuscular junction denervation, and axonal and motoneuron loss. DHT-treated SOD1-G93A mice demonstrates improvement in motor behavior as assessed by rota-rod and gait analyses, and an increased lifespan[2].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Bladder cancer cells
  • Concentrations: 1 nM
  • Incubation Time: 24 h
  • Method:

    Bladder cancer cells at a density of 50-60% confluence in 24-well plates are co-transfected with 250 ng of MMTV-luc reporter plasmid DNA and 2.5 ng of PRL-TK-luc plasmid DNA. After 6 h of transfection, the medium is replaced with another medium supplemented with charcoal-stripped FBS in the presence or absence of ligands (DHT, HF, or both) for 24 h. Cells were harvested, lysed, and assayed for luciferase activity.

Animal Research:

[2]

  • Animal Models: SOD1-G93A mutant mice with the congenic C57BL/6J background
  • Dosages: 5 mg
  • Administration: silastic implant

Solubility (25°C)

In vitro

DMSO 58 mg/mL
(199.69 mM)
Ethanol 58 mg/mL
(199.69 mM)
Water Insoluble

Chemical Information

Molecular Weight 290.44
Formula

C19H30O2

CAS No. 521-18-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05033444 Recruiting Drug: PRV-002|Drug: Placebo Traumatic Brain Injury (TBI) Odyssey Group International Inc.|Avance Clinical Pty Ltd. September 17 2021 Phase 1
NCT04989972 Not yet recruiting Drug: PSIL428|Dietary Supplement: Oyster mushroom Anxiety and Depression Wake Network Inc.|Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI September 15 2021 Phase 2
NCT05042895 Recruiting Procedure: Group A|Procedure: Group B Infertility Woman''s Health University Hospital Egypt August 20 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) supplier | purchase Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) cost | Dihydrotestosterone (DHT) manufacturer | order Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) distributor